研究者業績

渡辺 宏久

Hirohisa Watanabe

基本情報

所属
藤田医科大学 医学部 医学科
学位
博士(医学)(名古屋大学)

J-GLOBAL ID
200901016530045724
researchmap会員ID
1000369036

論文

 726
  • Ryunosuke Nagao, Yasuaki Mizutani, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Junichiro Yoshimoto, Hirohisa Watanabe
    European journal of neurology 31(3) e16158 2024年3月  
    BACKGROUND AND PURPOSE: Multiple system atrophy (MSA) is a neurodegenerative disease with characteristic motor and autonomic symptoms. Impaired brain serotonergic innervation can be associated with various clinical indices of MSA; however, the relationship between clinical symptoms and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA), a main serotonin metabolite, has not been fully elucidated. METHODS: To compare CSF 5-HIAA levels between patients with MSA and healthy controls, we included 33 controls and 69 MSA patients with either predominant parkinsonian or cerebellar ataxia subtypes. CSF 5-HIAA levels were measured using high-performance liquid chromatography. Additionally, we investigated correlations between CSF 5-HIAA and various clinical indices in 34 MSA patients. RESULTS: CSF 5-HIAA levels were significantly lower in MSA patients than in controls (p < 0.0001). Probable MSA patients had lower CSF 5-HIAA levels than possible MSA patients (p < 0.001). In MSA patients, CSF 5-HIAA levels were inversely correlated with scores in Parts 1, 2, and 4 of the Unified Multiple System Atrophy Rating Scale, and with systolic and diastolic blood pressure in Part 3. Structural equation modeling revealed significant paths between serotonin and clinical symptoms, and significance was highest for activities of daily living, walking, and body sway. CONCLUSIONS: Serotonin dysfunction, as assessed by CSF 5-HIAA levels, may implicate greater MSA severity.
  • Yusuke Fujioka, Kaori Kawai, Kuniyuki Endo, Minaka Ishibashi, Nobuyuki Iwade, Dilina Tuerde, Kozo Kaibuchi, Takayuki Yamashita, Akihiro Yamanaka, Masahisa Katsuno, Hirohisa Watanabe, Gen Sobue, Shinsuke Ishigaki
    Frontiers in neuroscience 18 1349366-1349366 2024年  
    Although dietary behaviors are affected by neuropsychiatric disorders, various environmental conditions can have strong effects as well. We found that mice under multiple stresses, including social isolation, intermittent high-fat diet, and physical restraint, developed feeding behavior patterns characterized by a deviated bait approach (fixated feeding). All the tested stressors affected dopamine release at the nucleus accumbens (NAcc) shell and dopamine normalization reversed the feeding defects. Moreover, inhibition of dopaminergic activity in the ventral tegmental area that projects into the NAcc shell caused similar feeding pattern aberrations. Given that the deviations were not consistently accompanied by changes in the amount consumed or metabolic factors, the alterations in feeding behaviors likely reflect perturbations to a critical stress-associated pathway in the mesolimbic dopamine system. Thus, deviations in feeding behavior patterns that reflect reward system abnormalities can be sensitive biomarkers of psychosocial and physical stress.
  • Akihiko Takashima, Riki Koike, Yoshiyuki Soeda, Yusuke Fujioka, Shinsuke Ishigaki, Hirohisa Watanabe
    Alzheimer's &amp; Dementia 19(S22) 2023年12月25日  
    Abstract Background We aimed to develop behavioral tasks that can identify early signs of Alzheimer’s disease (AD) in order to facilitate the development of preventative and therapeutic interventions. Method To do this, we created a 3D virtual reality task that is sensitive to the activity of grid cells in the entorhinal cortex, a region that is affected early on in AD. We tested path integration in a spatial navigation task in 177 volunteers between the ages of 20 and 89 who did not have a self‐diagnosed AD. Result Our results showed that the percentage of subjects showing impaired path integration correlated with the percentage of subjects showing neurofibrillary tangles in the entorhinal cortex, as seen in previously published autopsy data. To further confirm this relationship, we also tested a tauopathy mouse model and found that mice with accumulation of phosphorylated tau in the entorhinal cortex had impaired path integration without impairments in spatial cognition or novel object recognition. Conclusion These findings suggest that path integration deficit is caused by the accumulation of phosphorylated tau in the entorhinal cortex and may allow for early identification of individuals at risk for developing AD.
  • Yusuke Yoshida, Takamasa Yokoi, Kazuhiro Hara, Hirohisa Watanabe, Hiroshi Yamaguchi, Epifanio Bagarinao, Michihito Masuda, Toshiyasu Kato, Aya Ogura, Reiko Ohdake, Kazuya Kawabata, Masahisa Katsuno, Katsuhiko Kato, Shinji Naganawa, Nobuyuki Okamura, Kazuhiko Yanai, Gen Sobue
    Nagoya journal of medical science 85(4) 758-771 2023年11月  
    We aimed to elucidate the distribution pattern of the positron emission tomography probe [18F]THK 5351, a marker for astrogliosis and tau accumulation, in healthy aging. We also assessed the relationship between THK5351 retention and resting state networks. We enrolled 62 healthy participants in this study. All participants underwent magnetic resonance imaging/positron emission tomography scanning consisting of T1-weighted images, resting state functional magnetic resonance imaging, Pittsburgh Compound-B and THK positron emission tomography. The preprocessed THK images were entered into a scaled subprofile modeling/principal component analysis to extract THK distribution patterns. Using the most significant THK pattern, we generated regions of interest, and performed seed-based functional connectivity analyses. We also evaluated the functional connectivity overlap ratio to identify regions with high between-network connectivity. The most significant THK distributions were observed in the medial prefrontal cortex and bilateral putamen. The seed regions of interest in the medial prefrontal cortex had a functional connectivity map that significantly overlapped with regions of the dorsal default mode network. The seed regions of interest in the putamen showed strong overlap with the basal ganglia and anterior salience networks. The functional connectivity overlap ratio also showed that three peak regions had the characteristics of connector hubs. We have identified an age-related spatial distribution of THK in the medial prefrontal cortex and basal ganglia in normal aging. Interestingly, the distribution's peaks are located in regions of connector hubs that are strongly connected to large-scale resting state networks associated with higher cognitive function.
  • 小池 力, 添田 義行, 藤岡 祐介, 石垣 診祐, 渡辺 宏久, 畑 純一, 高島 明彦
    Dementia Japan 37(4) 708-708 2023年10月  
  • 島 さゆり, 大嶽 れい子, 高島 明彦, 徳田 隆彦, 石垣 診祐, 畑 純一, エピファニオ・バガリナオ, 笠井 淳史, 村手 健一郎, 水谷 泰彰, 植田 晃広, 伊藤 瑞規, 渡辺 宏久
    臨床神経学 63(Suppl.) S267-S267 2023年9月  
  • Chisako Iriyama, Kenichiro Murate, Sachiko Iba, Akinao Okamoto, Naoe Goto, Hideyuki Yamamoto, Toshiharu Kato, Keichiro Mihara, Takahiko Miyama, Keiko Hattori, Ryoko Kajiya, Masataka Okamoto, Yasuaki Mizutani, Seiji Yamada, Tetsuya Tsukamoto, Yuichi Hirose, Tatsuro Mutoh, Hirohisa Watanabe, Akihiro Tomita
    Cancer medicine 12(16) 16972-16984 2023年7月27日  
    BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. METHODS: In this study, we extracted cell-free DNA from the CSF (CSF-cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet-digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. RESULTS: Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF-cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF-cfDNA detected MYD88L265P and CD79Y196 mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18-93 days). CONCLUSIONS: These results suggest that mutation analysis using CSF-cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform.
  • Yasuaki Mizutani, Kazuki Nawashiro, Reiko Ohdake, Harutsugu Tatebe, Sayuri Shima, Akihiro Ueda, Junichiro Yoshimoto, Mizuki Ito, Takahiko Tokuda, Tatsuro Mutoh, Hirohisa Watanabe
    Annals of clinical and translational neurology 2023年7月26日  
    OBJECTIVE: Recent studies have revealed an association between Parkinson's disease (PD) and Fabry disease, a lysosomal storage disorder; however, the underlying mechanisms remain to be elucidated. This study aimed to investigate the enzymatic properties of serum alpha-galactosidase A (GLA) and compared them with the clinical parameters of PD. METHODS: The study participants consisted of 66 sporadic PD patients and 52 controls. We measured serum GLA activity and calculated the apparent Michaelis constant (Km ) and maximal velocity (Vmax ) by Lineweaver-Burk plot analysis. Serum GLA protein concentration was measured by enzyme-linked immunosorbent assay. We examined the potential correlations between serum GLA activity and GLA protein concentration and clinical features and the plasma neurofilament light chain (NfL) level. RESULTS: Compared to controls, PD patients showed significantly lower serum GLA activity (P < 0.0001) and apparent Vmax (P = 0.0131), but no change in the apparent Km value. Serum GLA protein concentration was lower in the PD group (P = 0.0168) and was positively associated with GLA activity. Serum GLA activity and GLA protein concentration in the PD group showed a negative correlation with age. Additionally, serum GLA activity was negatively correlated with the motor severity score and the level of plasma NfL, and was positively correlated with the score of frontal assessment battery. INTERPRETATION: This study highlights that the lower serum GLA activity in PD is the result of a quantitative decrement of GLA protein in the serum and that it may serve as a biomarker of disease severity.
  • Yasuaki Mizutani, Reiko Ohdake, Harutsugu Tatebe, Atsuhiro Higashi, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Takahiko Tokuda, Hirohisa Watanabe
    Journal of neurology 2023年7月22日  
    BACKGROUND: Parkinson's disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer's disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients. METHODS: Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson's disease (PDND) and 21 with Parkinson's disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke's Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores. RESULTS: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group. CONCLUSIONS: AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD.
  • 安達 隼輔, 大嶽 れい子, 建部 陽嗣, 東 篤宏, 長尾 龍之介, 前田 利樹, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 徳田 隆彦, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集 17回 91-91 2023年7月  
  • 神田 好加, 大嶽 れい子, 安達 隼輔, 河野 洋介, 辻村 優次, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 菊池 洸一, 東 篤宏, 長尾 龍之介, 前田 利樹, 廣田 政古, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集 17回 109-109 2023年7月  
  • 水谷 泰彰, 大嶽 れい子, 前田 康博, 東 篤宏, 前田 利樹, 長尾 龍之介, 島 さゆり, 植田 晃広, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集 17回 109-109 2023年7月  
  • 東 篤宏, 安達 隼輔, 神田 好加, 辻村 優次, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 前田 利樹, 長尾 龍之介, 廣田 政古, 大嶽 礼子, 島 さゆり, 水谷 泰彰, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集 17回 110-110 2023年7月  
  • 菊池 洸一, 水谷 泰彰, 中野 頌子, 林 和孝, 坂野 文彦, 廣田 政古, 島 さゆり, 植田 晃広, 渡辺 宏久
    臨床神経学 63(7) 482-482 2023年7月  
  • 安達 隼輔, 水谷 泰彰, 島 さゆり, 植田 晃広, 渡辺 宏久, 飯塚 高浩
    臨床神経学 63(7) 483-483 2023年7月  
  • Tomohiro Tada, Kazuhiro Hara, Naotoshi Fujita, Yoshinori Ito, Hiroshi Yamaguchi, Reiko Ohdake, Kazuya Kawabata, Aya Ogura, Toshiyasu Kato, Takamasa Yokoi, Michihito Masuda, Shinji Abe, Shinichi Miyao, Shinji Naganawa, Masahisa Katsuno, Hirohisa Watanabe, Gen Sobue, Katsuhiko Kato
    Annals of Nuclear Medicine 2023年5月9日  
    Abstract Objectives Standardised uptake value ratio (SUVR) is usually obtained by dividing the SUV of the region of interest (ROI) by that of the cerebellar cortex. Cerebellar cortex is not a valid reference in cases where amyloid β deposition or lesions are present. Only few studies have evaluated the use of other regions as references. We compared the validity of the pons and corpus callosum as reference regions for the quantitative evaluation of brain positron emission tomography (PET) using 11C-PiB compared to the cerebellar cortex. Methods We retrospectively evaluated data from 86 subjects with or without Alzheimer’s disease (AD). All subjects underwent magnetic resonance imaging, PET imaging, and cognitive function testing. For the quantitative analysis, three-dimensional ROIs were automatically placed, and SUV and SUVR were obtained. We compared these values between AD and healthy control (HC) groups. Results SUVR data obtained using the pons and corpus callosum as reference regions strongly correlated with that using the cerebellar cortex. The sensitivity and specificity were high when either the pons or corpus callosum was used as the reference region. However, the SUV values of the corpus callosum were different between AD and HC (p &lt; 0.01). Conclusions Our data suggest that the pons and corpus callosum might be valid reference regions.
  • Ryoichi Nakamura, Genki Tohnai, Masahiro Nakatochi, Naoki Atsuta, Hirohisa Watanabe, Daisuke Ito, Masahisa Katsuno, Akihiro Hirakawa, Yuishin Izumi, Mitsuya Morita, Takehisa Hirayama, Osamu Kano, Kazuaki Kanai, Nobutaka Hattori, Akira Taniguchi, Naoki Suzuki, Masashi Aoki, Ikuko Iwata, Ichiro Yabe, Kazumoto Shibuya, Satoshi Kuwabara, Masaya Oda, Rina Hashimoto, Ikuko Aiba, Tomohiko Ishihara, Osamu Onodera, Toru Yamashita, Koji Abe, Kouichi Mizoguchi, Toshio Shimizu, Yoshio Ikeda, Takanori Yokota, Kazuko Hasegawa, Fumiaki Tanaka, Kenji Nakashima, Ryuji Kaji, Jun-Ichi Niwa, Manabu Doyu, Chikashi Terao, Shiro Ikegawa, Koki Fujimori, Shiho Nakamura, Fumiko Ozawa, Satoru Morimoto, Kazunari Onodera, Takuji Ito, Yohei Okada, Hideyuki Okano, Gen Sobue
    Journal of neurology, neurosurgery, and psychiatry 94(10) 816-824 2023年5月4日  
    BACKGROUND: Several genetic factors are associated with the pathogenesis of sporadic amyotrophic lateral sclerosis (ALS) and its phenotypes, such as disease progression. Here, in this study, we aimed to identify the genes that affect the survival of patients with sporadic ALS. METHODS: We enrolled 1076 Japanese patients with sporadic ALS with imputed genotype data of 7 908 526 variants. We used Cox proportional hazards regression analysis with an additive model adjusted for sex, age at onset and the first two principal components calculated from genotyped data to conduct a genome-wide association study. We further analysed messenger RNA (mRNA) and phenotype expression in motor neurons derived from induced pluripotent stem cells (iPSC-MNs) of patients with ALS. RESULTS: Three novel loci were significantly associated with the survival of patients with sporadic ALS-FGF1 at 5q31.3 (rs11738209, HR=2.36 (95% CI, 1.77 to 3.15), p=4.85×10-9), THSD7A at 7p21.3 (rs2354952, 1.38 (95% CI, 1.24 to 1.55), p=1.61×10-8) and LRP1 at 12q13.3 (rs60565245, 2.18 (95% CI, 1.66 to 2.86), p=2.35×10-8). FGF1 and THSD7A variants were associated with decreased mRNA expression of each gene in iPSC-MNs and reduced in vitro survival of iPSC-MNs obtained from patients with ALS. The iPSC-MN in vitro survival was reduced when the expression of FGF1 and THSD7A was partially disrupted. The rs60565245 was not associated with LRP1 mRNA expression. CONCLUSIONS: We identified three loci associated with the survival of patients with sporadic ALS, decreased mRNA expression of FGF1 and THSD7A and the viability of iPSC-MNs from patients. The iPSC-MN model reflects the association between patient prognosis and genotype and can contribute to target screening and validation for therapeutic intervention.
  • Toshiharu Nagatsu, Akira Nakashima, Hirohisa Watanabe, Shosuke Ito, Kazumasa Wakamatsu, Fabio A. Zucca, Luigi Zecca, Moussa Youdim, Maximilian Wulf, Peter Riederer, Johannes M. Dijkstra
    Journal of Neural Transmission 2023年3月20日  
    Abstract The dark pigment neuromelanin (NM) is abundant in cell bodies of dopamine (DA) neurons in the substantia nigra (SN) and norepinephrine (NE) neurons in the locus coeruleus (LC) in the human brain. During the progression of Parkinson’s disease (PD), together with the degeneration of the respective catecholamine (CA) neurons, the NM levels in the SN and LC markedly decrease. However, questions remain among others on how NM is associated with PD and how it is synthesized. The biosynthesis pathway of NM in the human brain has been controversial because the presence of tyrosinase in CA neurons in the SN and LC has been elusive. We propose the following NM synthesis pathway in these CA neurons: (1) Tyrosine is converted by tyrosine hydroxylase (TH) to L-3,4-dihydroxyphenylalanine (L-DOPA), which is converted by aromatic L-amino acid decarboxylase to DA, which in LC neurons is converted by dopamine β-hydroxylase to NE; (2) DA or NE is autoxidized to dopamine quinone (DAQ) or norepinephrine quinone (NEQ); and (3) DAQ or NEQ is converted to eumelanic NM (euNM) and pheomelanic NM (pheoNM) in the absence and presence of cysteine, respectively. This process involves proteins as cysteine source and iron. We also discuss whether the NM amounts per neuromelanin-positive (NM+) CA neuron are higher in PD brain, whether NM quantitatively correlates with neurodegeneration, and whether an active lifestyle may reduce NM formation.
  • 河野 洋介, 島 さゆり, 長尾 龍之介, 加藤 邦尚, 中野 頌子, 林 和孝, 坂野 文彦, 菊池 洸一, 村手 健一郎, 廣田 政古, 水谷 泰彰, 植田 晃広, 大嶽 れい子, 伊藤 瑞規, 渡辺 宏久
    臨床神経学 63(3) 182-182 2023年3月  
  • 辻村 優次, 神田 好加, 河野 洋介, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 菊池 洸一, 長尾 龍之介, 村手 健一郎, 廣田 政古, 水谷 泰彰, 島 さゆり, 武藤 多津郎, 吉田 眞理, 渡辺 宏久
    臨床神経学 63(3) 189-189 2023年3月  
  • Takayasu Mishima, Shih-Wei Chiu, Hidemoto Saiki, Takuhiro Yamaguchi, Yasushi Shimo, Tetsuya Maeda, Hirohisa Watanabe, Kenichi Kashihara, Masahiro Nomoto, Nobutaka Hattori, Yoshio Tsuboi
    Journal of the Neurological Sciences 120619-120619 2023年3月  
  • Mayumi Senda, Akihiro Ueda, Mizuki Ito, Sayuri Shima, Yasuaki Mizutani, Tatsuro Mutoh, Hirohisa Watanabe
    Fujita medical journal 9(1) 35-40 2023年2月  
    OBJECTIVE: In this study, we aimed to clarify the relationship between initial treatment response, prednisolone (PSL) dosage, clinical type, and recurrence in patients with hypertrophic pachymeningitis (HP). METHODS: The study cohort comprised eight patients with HP who had been admitted to our hospital from April 2015 to June 2020. Diagnostic criteria for HP included neurological abnormalities and dural thickening on magnetic resonance gadolinium-enhanced T1-weighted images. RESULTS: Relevant characteristics of the eight study patients are as follows. There were two men and six women. The average age at onset was 58.3 (range: 29-79) years. Three of them had myeloperoxidase-antineutrophil cytoplasmic antibody-related vasculitis, one immunoglobulin G4-related disease, and one ulcerative colitis. The remaining three patients had idiopathic HP. The average maximum dosage of PSL was 0.79 mg/kg/day, and the average daily maintenance dosage 0.18 mg/kg/day. Three patients needed additional immunosuppressive drugs. Both idiopathic and secondary HP initially responded well to PSL, with improvement in activities of daily living. Six patients had some sequelae related to cranial nerve involvement. No relapses occurred while the patients were taking moderate doses of PSL; however, all patients with idiopathic HP had recurrences when their PSL dosage was reduced. CONCLUSIONS: Patients with idiopathic HP and HP associated with immune disorders respond to steroids and immunosuppressive drugs and recover well. However, there is a high rate of relapse after reduction of PSL dosage, mainly in those with idiopathic HP.
  • Reiko Ohdake, Hirohisa Watanabe, Kazuya Kawabata, Aya Ogura, Maki Sato, Yasuhiro Tanaka, Kazunori Imai, Michihito Masuda, Toshiyasu Kato, Takamasa Yokoi, Kazuhiro Hara, Ryoichi Nakamura, Naoki Atsuta, Masafumi Nakagawa, Masahisa Katsuno, Gen Sobue
    Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 38(1) 57-71 2023年1月21日  
    OBJECTIVE: About 30%-50% of patients with amyotrophic lateral sclerosis (ALS) show cognitive impairment ranging from mild dysexecutive syndrome to frontotemporal dementia. We aimed to develop a brief cognitive test, convenient auditory-based language and executive function test (CABLET), for rapid detection of cognitive impairment in ALS, with reduced load on motor function. METHOD: The CABLET comprises two tests using auditory verbal stimuli: Test 1, assessing word repetition and lexical judgment, and Test 2, evaluating verbal short-term memory and semantics knowledge. The administration time of Test 1 and Test 2 was 1 and 3-5 min, respectively. Overall, 61 patients with ALS and 46 age-, sex-, and education-matched healthy controls participated in this study. All participants underwent existing neuropsychological tests and the CABLET. We investigated the applicability of the CABLET to detect ALS with cognitive impairment (ALSci) from normal cognition. RESULTS: Receiver operating characteristic analyses showed that both the CABLET total and Test 2 had good diagnostic accuracy (area under the curve [AUC]: total = 0.894, Test 2 = 0.893). Test 2 had the highest sensitivity (100% sensitivity and 71.4% specificity). No significant difference existed in the AUC between the analyses with and without age, education, and disease severity as covariates. Correlations were observed between the CABLET and established neuropsychological tests, supporting its good convergent validity. CONCLUSIONS: Our findings indicated that the CABLET could be useful in identifying ALSci quickly without adjusting for confounding factors. Further validation is required to evaluate it in larger groups and compare with ALS-specific cognitive screen.
  • 尚 聡, 乾 好貴, 市原 隆, 外山 宏, 長尾 龍之介, 水谷 泰彰, 伊藤 瑞規, 渡辺 宏久, 石黒 雅伸
    核医学 60(1) 20-20 2023年  
  • Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito
    Journal of movement disorders 16(1) 13-21 2023年1月  
    This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.
  • 渡辺 宏久, 大嶽 れい子, 高島 明彦, 徳田 隆彦, 石垣 診祐, 畑 純一, ばがりなお・えぴふぁにお, 村手 健一郎, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規
    臨床神経学 62(Suppl.) S225-S225 2022年10月  
  • 廣田 政古, 加藤 邦尚, 新美 芳樹, 林 和孝, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 信二, 渡辺 宏久
    臨床神経学 62(Suppl.) S319-S319 2022年10月  
  • 植田 晃広, 島 さゆり, 前田 利樹, 石川 等真, 水野 正美, 大嶽 れい子, 安達 隼輔, 中野 頌子, 林 和孝, 坂野 文彦, 加藤 邦尚, 東 篤宏, 菊池 洸一, 長尾 龍之介, 村手 健一郎, 廣田 政古, 水谷 泰彰, 伊藤 瑞規, 伊藤 信二, 武藤 多津郎, 渡辺 宏久
    神経免疫学 27(1) 151-151 2022年10月  
  • 林 和孝, 水谷 泰彰, 江坂 好加, 辻村 優次, 安達 隼輔, 中野 頌子, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 前田 利樹, 長尾 龍之介, 村手 健一郎, 石川 等真, 廣田 政古, 島 さゆり, 伊藤 瑞規, 植田 晃広, 伊藤 信二, 渡辺 宏久
    臨床神経学 62(Suppl.) S206-S206 2022年10月  
  • 長尾 龍之介, 水谷 泰彰, 伊藤 瑞規, 辻村 優次, 江坂 好加, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 前田 利樹, 村手 健一郎, 廣田 政古, 島 さゆり, 植田 晃広, 伊藤 信二, 外山 宏, 渡辺 宏久
    臨床神経学 62(Suppl.) S208-S208 2022年10月  
  • 江坂 好加, 安達 隼輔, 辻村 優次, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S216-S216 2022年10月  
  • 渡辺 宏久, 大嶽 れい子, 高島 明彦, 徳田 隆彦, 石垣 診祐, 畑 純一, ばがりなお・えぴふぁにお, 村手 健一郎, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規
    臨床神経学 62(Suppl.) S225-S225 2022年10月  
  • 加藤 邦尚, 安達 隼輔, 辻村 優次, 江坂 好加, 中野 頌子, 林 和孝, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S241-S241 2022年10月  
  • 石川 等真, 大嶽 れい子, 安達 隼輔, 辻村 優次, 江坂 好加, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S258-S258 2022年10月  
  • 千田 麻友美, 植田 晃広, 伊藤 瑞規, 加子 哲治, 中野 頌子, 島 さゆり, 水谷 泰彰, 渡辺 宏久
    臨床神経学 62(Suppl.) S262-S262 2022年10月  
  • 島 さゆり, 水谷 泰彰, 江坂 好加, 辻村 優次, 安達 隼輔, 中野 頌子, 林 和孝, 坂野 文彦, 加藤 邦尚, 東 篤宏, 菊池 洸一, 前田 利樹, 長尾 龍之介, 廣田 政古, 村手 健一郎, 植田 晃広, 伊藤 瑞規, 伊藤 信二, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S265-S265 2022年10月  
  • 菊池 洸一, 大嶽 れい子, 江坂 好加, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S281-S281 2022年10月  
  • 辻村 優次, 江坂 好加, 安達 隼輔, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S282-S282 2022年10月  
  • 中野 頌子, 大嶽 れい子, 辻村 優次, 江坂 好加, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S283-S283 2022年10月  
  • 村手 健一郎, 大嶽 れい子, 安達 隼輔, 辻村 優次, 江坂 好加, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学 62(Suppl.) S305-S305 2022年10月  
  • 坂野 文彦, 水谷 泰彰, 江坂 好加, 辻村 優次, 林 和孝, 加藤 邦尚, 東 篤宏, 菊池 洸一, 前田 利樹, 長尾 龍之介, 村手 健一郎, 廣田 政子, 石川 等真, 島 さゆり, 植田 晃広, 伊藤 瑞規, 伊藤 信二, 村山 和宏, 外山 宏, 渡辺 宏久
    臨床神経学 62(Suppl.) S325-S325 2022年10月  
  • 東 篤宏, 大嶽 れい子, 安達 隼輔, 辻村 優次, 江坂 好加, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 菊池 洸一, 前田 利樹, 長尾 龍之介, 石川 等真, 廣田 政古, 村手 健一郎, 島 さゆり, 水谷 泰彰, 植田 晃広, 伊藤 瑞規, 渡辺 宏久
    臨床神経学 62(Suppl.) S327-S327 2022年10月  
  • 大嶽 れい子, 渡辺 宏久, 桝田 道人, 坂口 巧一, 花井 俊哉, 鈴木 麻希, 渡部 宏幸, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 橋本 衛, 勝野 雅央, 加藤 昇平, 池田 学, 祖父江 元
    臨床神経学 62(Suppl.) S394-S394 2022年10月  
  • 朝倉 真生, 水谷 泰彰, 中野 頌子, 林 和孝, 坂野 文彦, 加藤 邦尚, 菊池 洸一, 東 篤宏, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 河村 吉紀, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 吉川 哲史, 渡辺 宏久
    臨床神経学 62(Suppl.) S414-S414 2022年10月  
  • 河村 吉紀, 水谷 泰彰, 長尾 龍之介, 朝倉 真生, 小澤 慶, 古川 源, 吉兼 綾美, 石原 尚子, 渡辺 宏久, 吉川 哲史
    NEUROINFECTION 27(2) 228-228 2022年10月  
  • Noriko Nishikawa, Miho Murata, Taku Hatano, Yohei Mukai, Yuji Saitoh, Takashi Sakamoto, Takashi Hanakawa, Yuichi Kamei, Hisateru Tachimori, Kenji Hatano, Hiroshi Matsuda, Yosuke Taruno, Nobukatsu Sawamoto, Yuta Kajiyama, Kensuke Ikenaka, Kazuya Kawabata, Tomohiko Nakamura, Hirotaka Iwaki, Hiroshi Kadotani, Yukiyoshi Sumi, Yuichi Inoue, Toshihiro Hayashi, Takeshi Ikeuchi, Yasushi Shimo, Hideki Mochizuki, Hirohisa Watanabe, Nobutaka Hattori, Yuji Takahashi, Ryosuke Takahashi
    Parkinsonism &amp; Related Disorders 103 129-135 2022年9月  
  • Epifanio Bagarinao, Kazuya Kawabata, Hirohisa Watanabe, Kazuhiro Hara, Reiko Ohdake, Aya Ogura, Michihito Masuda, Toshiyasu Kato, Satoshi Maesawa, Masahisa Katsuno, Gen Sobue
    Brain Communications 2022年8月20日  
  • Kazuya Kawabata, Epifanio Bagarinao, Hirohisa Watanabe, Satoshi Maesawa, Daisuke Mori, Kazuhiro Hara, Reiko Ohdake, Michihito Masuda, Aya Ogura, Toshiyasu Kato, Shuji Koyama, Masahisa Katsuno, Toshihiko Wakabayashi, Masafumi Kuzuya, Minoru Hoshiyama, Haruo Isoda, Shinji Naganawa, Norio Ozaki, Gen Sobue
    NeuroImage 257 119263-119263 2022年8月15日  
    Accumulating evidence from anatomical and neuroimaging studies suggests that the cerebellum is engaged in a variety of motor and cognitive tasks. Given its various functions, a key question is whether the cerebellum also plays an important role in the brain's integrative functions. Here, we hypothesize the existence of connector regions, also known as connector hubs, where multiple resting state networks converged in the cerebellum. To verify this, we employed a recently developed voxel-level network measure called functional connectivity overlap ratio (FCOR), which could be used to quantify the spatial extent of a region's connection to several large-scale cortical networks. Using resting state functional MRI data from 101 healthy participants, cerebellar FCOR maps were constructed and used to identify the locations of connector hubs in the cerebellum. Results showed that a number of cerebellar regions exhibited strong connectivity with multiple functional networks, verifying our hypothesis. These highly connected regions were located in the posterior cerebellum, especially in lobules VI, VII, and IX, and mainly connected to the core neurocognitive networks such as default mode and executive control networks. Regions associated with the sensorimotor network were also localized in lobule V, VI, and VIII, albeit in small clusters. These cerebellar connector hubs may play an essential role in the processing of information across the core neurocognitive networks.
  • Sanae Kato, Epifanio Bagarinao, Haruo Isoda, Shuji Koyama, Hirohisa Watanabe, Satoshi Maesawa, Kazuhiro Hara, Masahisa Katsuno, Shinji Naganawa, Norio Ozaki, Gen Sobue
    Radiological Physics and Technology 15(4) 298-310 2022年8月12日  
  • Sachiko Kato, Satoshi Maesawa, Epifanio Bagarinao, Daisuke Nakatsubo, Takahiko Tsugawa, Satomi Mizuno, Kazuya Kawabata, Takashi Tsuboi, Masashi Suzuki, Masashi Shibata, Sou Takai, Tomotaka Ishizaki, Jun Torii, Manabu Mutoh, Ryuta Saito, Toshihiko Wakabayashi, Masahisa Katsuno, Norio Ozaki, Hirohisa Watanabe, Gen Sobue
    Journal of neurosurgery 138(2) 1-12 2022年7月8日  
    OBJECTIVE: Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy ameliorates symptoms in patients with essential tremor (ET). How this treatment affects canonical brain networks has not been elucidated. The purpose of this study was to clarify changes of brain networks after MRgFUS thalamotomy in ET patients by analyzing resting-state networks (RSNs). METHODS: Fifteen patients with ET were included in this study. Left MRgFUS thalamotomy was performed in all cases, and MR images, including resting-state functional MRI (rsfMRI), were taken before and after surgery. MR images of 15 age- and sex-matched healthy controls (HCs) were also used for analysis. Using rsfMRI data, canonical RSNs were extracted by performing dual regression analysis, and the functional connectivity (FC) within respective networks was compared among pre-MRgFUS patients, post-MRgFUS patients, and HCs. The severity of tremor was evaluated using the Clinical Rating Scale for Tremor (CRST) score pre- and postoperatively, and its correlation with RSNs was examined. RESULTS: Preoperatively, ET patients showed a significant decrease in FC in the sensorimotor network (SMN), primary visual network (VN), and visuospatial network (VSN) compared with HCs. The decrease in FC in the SMN correlated with the severity of tremor. After MRgFUS thalamotomy, ET patients still exhibited a significant decrease in FC in a small area of the SMN, but they exhibited an increase in the cerebellar network (CN). In comparison between pre- and post-MRgFUS patients, the FC in the SMN and the VSN significantly increased after treatment. Quantitative evaluation of the FCs in these three groups showed that the SMN and VSN increased postoperatively and demonstrated a trend toward those of HCs. CONCLUSIONS: The SMN and CN, which are considered to be associated with the cerebello-thalamo-cortical loop, exhibited increased connectivity after MRgFUS thalamotomy. In addition, the FC of the visual network, which declined in ET patients compared with HCs, tended to normalize postoperatively. This could be related to the hypothesis that visual feedback is involved in tremor severity in ET patients. Overall, the analysis of the RSNs by rsfMRI reflected the pathophysiology with the intervention of MRgFUS thalamotomy in ET patients and demonstrated a possibility of a biomarker for successful treatment.

MISC

 103

書籍等出版物

 6

共同研究・競争的資金等の研究課題

 24

その他

 2
  • 創薬へ向けたシーズ利用 本研究ニーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進セン ター(fuji-san@fujita-hu.ac.jp)まで
  • シーズ名称:神経変性疾患の臨床、血液、髄液、画像データ 本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進セン ター(fuji-san@fujita-hu.ac.jp)まで